Susquehanna International Group
KNTE

Susquehanna International Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Susquehanna International Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,700
Closed -$65.7K – 13589
2024
Q1 		$65.7K Buy
+24,700
New +$61.1K ﹤0.01% 11440
2023
Q2 		– Sell
-38,100
Closed -$238K – 13473
2023
Q1 		$238K Buy
+38,100
New +$232K ﹤0.01% 10219
2022
Q4 		– Sell
-23,500
Closed -$281K – 14073
2022
Q3 		$281K Sell
23,500
-1,200
-5% -$15.7K ﹤0.01% 9961
2022
Q2 		$311K Buy
24,700
+4,400
+22% +$41K ﹤0.01% 9476
2022
Q1 		$229K Buy
+20,300
New +$223K ﹤0.01% 10924

Susquehanna International Group's KNTE Position: Q2 2024 in Review

Susquehanna International Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 526,021 shares — an estimated $1.4M sold.

Susquehanna International Group first reported a position in KNTE in Q4 2021 and held it in 7 quarters. The position peaked at $1.4M in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Susquehanna International Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 526,021 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $1.4M.
  • Susquehanna International Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Susquehanna International Group's Kinnate Biopharma Inc. Common Stock position peaked at $1.4M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.